Second Sight Medical Products (EYES) Earns Daily Coverage Optimism Rating of 0.05

News stories about Second Sight Medical Products (NASDAQ:EYES) have trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Second Sight Medical Products earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned media coverage about the medical device company an impact score of 46.0597279002689 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:

Shares of Second Sight Medical Products stock traded up $0.06 during midday trading on Friday, reaching $1.61. The company had a trading volume of 283,506 shares, compared to its average volume of 190,812. The firm has a market cap of $103.97 million, a P/E ratio of -2.73 and a beta of 3.08. Second Sight Medical Products has a fifty-two week low of $0.90 and a fifty-two week high of $2.58.

Second Sight Medical Products (NASDAQ:EYES) last issued its earnings results on Tuesday, August 7th. The medical device company reported ($0.12) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.02. The business had revenue of $1.91 million during the quarter, compared to the consensus estimate of $2.21 million. Second Sight Medical Products had a negative return on equity of 432.45% and a negative net margin of 418.82%. analysts predict that Second Sight Medical Products will post -0.58 EPS for the current year.

A number of research firms recently commented on EYES. HC Wainwright set a $5.00 price objective on Second Sight Medical Products and gave the stock a “buy” rating in a research note on Wednesday. Zacks Investment Research lowered Second Sight Medical Products from a “buy” rating to a “hold” rating in a research note on Tuesday, July 17th. Finally, ValuEngine raised Second Sight Medical Products from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.

In other Second Sight Medical Products news, Director Gregg Williams bought 26,485 shares of the stock in a transaction on Monday, June 4th. The stock was acquired at an average cost of $1.95 per share, for a total transaction of $51,645.75. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Edward David Randolph sold 16,023 shares of Second Sight Medical Products stock in a transaction that occurred on Friday, June 1st. The stock was sold at an average price of $1.96, for a total value of $31,405.08. Following the completion of the sale, the vice president now owns 16,045 shares of the company’s stock, valued at $31,448.20. The disclosure for this sale can be found here. Over the last quarter, insiders acquired 324,803 shares of company stock valued at $584,633 and sold 27,213 shares valued at $54,164. Insiders own 34.70% of the company’s stock.

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc, together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. It offers Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa.

Featured Article: Marijuana Stocks Future Looks Bright

Insider Buying and Selling by Quarter for Second Sight Medical Products (NASDAQ:EYES)

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with's FREE daily email newsletter.

Leave a Reply